These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17689538)

  • 1. E-cadherin expression in cervical epithelial cells of postmenopausal women: association with hormone therapy, tibolone, and raloxifene.
    Sioulas V; Christodoulakos G; Lambrinoudaki I; Politi E; Sergentanis TN; Creatsas G
    Fertil Steril; 2008 Apr; 89(4):1018-20. PubMed ID: 17689538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does hormone therapy, tibolone or raloxifene modify VEGF expression in cervical epithelial cells?
    Sioulas VD; Politi E; Rizos D; Augoulea A; Kyroudi A; Sergentanis TN; Panoulis C; Aravantinos L; Creatsa M; Lambrinoudaki I
    Climacteric; 2012 Apr; 15(2):181-5. PubMed ID: 22066937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.
    Christodoulakos GE; Botsis DS; Lambrinoudaki IV; Papagianni VD; Panoulis CP; Creatsa MG; Alexandrou AP; Augoulea AD; Dendrinos SG; Creatsas GC
    Maturitas; 2006 Mar; 53(4):413-23. PubMed ID: 16140483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials.
    Biglia N; Maffei S; Lello S; Nappi RE
    Gynecol Endocrinol; 2010 Nov; 26(11):804-14. PubMed ID: 20586550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids, apolipoprotein A1, apolipoprotein B and lipoprotein(a) in Greek postmenopausal women.
    Christodoulakos GE; Lambrinoudaki IV; Panoulis CP; Papadias CA; Kouskouni EE; Creatsas GC
    Gynecol Endocrinol; 2004 May; 18(5):244-57. PubMed ID: 15346660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short and long term effects of tibolone in postmenopausal women.
    Formoso G; Perrone E; Maltoni S; Balduzzi S; D'Amico R; Bassi C; Basevi V; Marata AM; Magrini N; Maestri E
    Cochrane Database Syst Rev; 2012 Feb; (2):CD008536. PubMed ID: 22336846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The positive predictive value of cervical smears in previously screened postmenopausal women: the Heart and Estrogen/progestin Replacement Study (HERS).
    Sawaya GF; Grady D; Kerlikowske K; Valleur JL; Barnabei VM; Bass K; Snyder TE; Pickar JH; Agarwal SK; Mandelblatt J
    Ann Intern Med; 2000 Dec; 133(12):942-50. PubMed ID: 11119395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer.
    Nelson HD; Fu R; Griffin JC; Nygren P; Smith ME; Humphrey L
    Ann Intern Med; 2009 Nov; 151(10):703-15, W-226-35. PubMed ID: 19920271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system.
    Eilertsen AL; Liestøl S; Mowinckel MC; Hemker HC; Sandset PM
    Thromb Haemost; 2007 Jun; 97(6):938-43. PubMed ID: 17549295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women.
    Delmas PD; Davis SR; Hensen J; Adami S; van Os S; Nijland EA
    Osteoporos Int; 2008 Aug; 19(8):1153-60. PubMed ID: 18256777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of tibolone and raloxifene on health-related quality of life and sexual function.
    Nijland EA; Weijmar Schultz WC; Davis SR
    Maturitas; 2007 Oct; 58(2):164-73. PubMed ID: 17870260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum lipids and apolipoproteins in Greek postmenopausal women: association with estrogen, estrogen-progestin, tibolone and raloxifene therapy.
    Creatsas G; Christodoulakos G; Lambrinoudaki I; Panoulis C; Chondros C; Patramanis P
    J Endocrinol Invest; 2003 Jun; 26(6):545-51. PubMed ID: 12952369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density.
    Lundström E; Christow A; Kersemaekers W; Svane G; Azavedo E; Söderqvist G; Mol-Arts M; Barkfeldt J; von Schoultz B
    Am J Obstet Gynecol; 2002 Apr; 186(4):717-22. PubMed ID: 11967497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women: a prospective study.
    Christodoulakos GE; Lambrinoudaki IV; Vourtsi AD; Panoulis KP; Kelekis DA; Creatsas GC
    Menopause; 2002; 9(2):110-6. PubMed ID: 11875329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-6 and flow-mediated dilatation as markers of increased vascular inflammation in women receiving hormone therapy.
    Vitale C; Cornoldi A; Gebara O; Silvestri A; Wajngarten M; Cerquetani E; Fini M; Ramires JA; Rosano GM
    Menopause; 2005; 12(5):552-8. PubMed ID: 16145309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: a placebo-controlled randomized trial.
    Strickler R; Stovall DW; Merritt D; Shen W; Wong M; Silfen SL
    Obstet Gynecol; 2000 Sep; 96(3):359-65. PubMed ID: 10960626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of resveratrol, raloxifene, tibolone and conjugated equine estrogen on vaginal squamous cell maturation of ovariectomized rats.
    Hascalik S; Celik O; Tamser M; Mizrak B
    Gynecol Obstet Invest; 2005; 60(4):186-91. PubMed ID: 16020933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer.
    Dimitrakakis C; Keramopoulos D; Vourli G; Gaki V; Bredakis N; Keramopoulos A
    Climacteric; 2005 Dec; 8(4):342-51. PubMed ID: 16390769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptosis in the endometrium of postmenopausal women receiving tibolone.
    Gökaslan H; Oktem O; Durmuşoglu F; Eren F
    Gynecol Obstet Invest; 2003; 56(3):124-7. PubMed ID: 14504425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tibolone and risk of endometrial polyps: a prospective, comparative study with hormone therapy.
    Perez-Medina T; Bajo-Arenas J; Haya J; Sanfrutos L; Iniesta S; Bueno B; Castelo-Branco C
    Menopause; 2003; 10(6):534-7. PubMed ID: 14627862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.